685 related articles for article (PubMed ID: 16319908)
1. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
2. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Neuropsychopharmacology; 2007 Jul; 32(7):1540-9. PubMed ID: 17164815
[TBL] [Abstract][Full Text] [Related]
4. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
5. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1165-78. PubMed ID: 21087552
[TBL] [Abstract][Full Text] [Related]
6. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.
Natesan S; Svensson KA; Reckless GE; Nobrega JN; Barlow KB; Johansson AM; Kapur S
J Pharmacol Exp Ther; 2006 Aug; 318(2):810-8. PubMed ID: 16648369
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Leite JV; Guimarães FS; Moreira FA
Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
[TBL] [Abstract][Full Text] [Related]
8. Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.
Carboni L; Negri M; Michielin F; Bertani S; Fratte SD; Oliosi B; Cavanni P
Int J Neuropsychopharmacol; 2012 Jun; 15(5):645-56. PubMed ID: 21733233
[TBL] [Abstract][Full Text] [Related]
9. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
10. The antipsychotic potential of l-stepholidine--a naturally occurring dopamine receptor D1 agonist and D2 antagonist.
Natesan S; Reckless GE; Barlow KB; Odontiadis J; Nobrega JN; Baker GB; George SR; Mamo D; Kapur S
Psychopharmacology (Berl); 2008 Aug; 199(2):275-89. PubMed ID: 18521575
[TBL] [Abstract][Full Text] [Related]
11. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects.
Wadenberg ML; Soliman A; VanderSpek SC; Kapur S
Neuropsychopharmacology; 2001 Nov; 25(5):633-41. PubMed ID: 11682246
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Grunder G; Carlsson A; Wong DF
Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
[TBL] [Abstract][Full Text] [Related]
13. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats.
Nordquist RE; Risterucci C; Moreau JL; von Kienlin M; Künnecke B; Maco M; Freichel C; Riemer C; Spooren W
Neuropharmacology; 2008 Feb; 54(2):405-16. PubMed ID: 18054053
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics.
Bardin L; Auclair A; Kleven MS; Prinssen EP; Koek W; Newman-Tancredi A; Depoortère R
Behav Pharmacol; 2007 Mar; 18(2):103-18. PubMed ID: 17351418
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z; Ichikawa J; Dai J; Meltzer HY
Eur J Pharmacol; 2004 Jun; 493(1-3):75-83. PubMed ID: 15189766
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats.
Oshibuchi H; Inada K; Sugawara H; Ishigooka J
Eur J Pharmacol; 2009 Aug; 615(1-3):83-90. PubMed ID: 19477171
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
Koener B; Goursaud S; Van De Stadt M; Calas AG; Jeanjean AP; Maloteaux JM; Hermans E
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):65-77. PubMed ID: 21061116
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
19. Contrasting loxapine to its isomer isoloxapine--the critical role of in vivo D2 blockade in determining atypicality.
Natesan S; Vanderspek S; Nobrega JN; McClelland RA; Kapur S
Schizophr Res; 2005 Sep; 77(2-3):189-99. PubMed ID: 15925489
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
Wood MD; Scott C; Clarke K; Westaway J; Davies CH; Reavill C; Hill M; Rourke C; Newson M; Jones DN; Forbes IT; Gribble A
Eur J Pharmacol; 2006 Sep; 546(1-3):88-94. PubMed ID: 16925992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
